DVAX (Dynavax Technologies) ROE % Adjusted to Book Value : 1.65% (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies ROE % Adjusted to Book Value?

Dynavax Technologies's ROE % for the quarter that ended in Dec. 2024 was 4.41%. Dynavax Technologies's PB Ratio for the quarter that ended in Dec. 2024 was 2.68. Dynavax Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 1.65%.

Dynavax Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Dynavax Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies ROE % Adjusted to Book Value Chart

Dynavax Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-26.90

7.02

31.19

-0.36

1.67

Dynavax Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.05	-2.14	3.15	4.94	1.65

Competitive Comparison of Dynavax Technologies's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dynavax Technologies's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's ROE % Adjusted to Book Value falls into.

Dynavax Technologies ROE % Adjusted to Book Value Calculation

Dynavax Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	4.48%	/	2.68
	=	1.67%

Dynavax Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	4.41%	/	2.68
	=	1.65%

Dynavax Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

0IDA:UK DYF1:Germany DYF1:Germany

Address

2100 Powell Street, Suite 720, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Executives

David F Novack	officer: Senior Vice President	39 YORKSHIRE DR, OAKLAND CA 94618
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Justin Burgess	officer: Principal Accounting Officer	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Robert Janssen	officer: Chief Medical Officer and VP	C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Ryan Spencer	officer: Co-President and Senior VP	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Elaine D Sun	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald	officer: SVP and CFO	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman	officer: Chief Science Officer and VP	C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach	officer: VP, CBO, and General Counsel	1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063